Pharmaceuticals India News
  • Home
  • Brands
    • Alkem
    • Apollo Hospital
    • Aurobindo Pharma
    • Biocon
    • Cipla
    • Divi’s Laboratories
    • Dr Reddy’s
    • Fortis
    • Glenmark
    • Lupin
    • Mankind Pharma
    • Natco
    • Pfizer
    • Piramal Pharma
    • Sun Pharma
    • Torrent Pharma
    • Zydus
Select Page
Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.

Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.

by Team Small News | Jan 12, 2026 | Pharma, Zydus

The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a...

Alkem’s Renocia kit offers a cyclical nutritional supplement therapy designed to promote healthy hair growth.

by Team Small News | Jan 12, 2026 | Alkem, Pharma

Alkem Laboratories has launched a new product called Renocia cyclical therapy kit, a weekly nutritional supplementation regimen designed to support hair growth, strengthen hair follicles, and manage hair loss. The kit contains a set of vegetarian-sourced supplements,...

Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.

by Team Small News | Jan 10, 2026 | Aurobindo Pharma, Pharma

A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether...

Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.

by Team Small News | Jan 7, 2026 | Biocon, Pharma

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and...

The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.

by Team Small News | Jan 7, 2026 | Natco, Pharma

The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to...
Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.

Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.

by Team Small News | Jan 6, 2026 | Pharma, Sun Pharma

The Bombay High Court has ruled in favor of Eris Lifesciences, dismissing Sun Pharmaceutical’s claim that Eris’s medication “EsiRaft” infringed on Sun Pharma’s trademark for their medication “Raciraft”. The court found that...
« Older Entries
Next Entries »

_________

Pharna Brands

  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma
  • Torrent Pharma
  • Zydus
  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Torrent Pharma
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Zydus
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma

    Designed by Elegant Themes | Powered by WordPress